Iryna Mezhiievska, Valerii Ivanov, Valentyn Maslovskyi


The aim. Estimation of ST2 plasma level in patients with acute myocardial infarction without ST elevation (NSTEMI) and its relationship with different clinical characteristics.

Materials and methods. 165 patients aged from 35 to 79 (average of 60.7±0.8 years) with various forms of coronary artery disease (CAD) with and without arterial hypertension were examined. The variability of plasma ST2 level in different forms of CAD and in NSTEMI group was analyzed depending on gender-age and clinical characteristics and features of the disease course.


The results of the present investigation were that the ST2 level in the main cohort was in range from 5.5 to 233.9 (in the middle – 49.8±3.5 ng / ml (median indicator – 34.7 and the interquartile range – 21.9 and 59.1 respectively).

Significantly higher ST2 levels were found in patients with NSTEMI, unlike the comparison group, in the median analysis (35.9 vs. 27.7 ng/ml, p=0.047) and no statistical differences were observed in the mean values.

In patients with NSTEMI, a certain association of ST2 level in plasma with the MI course was detected. A higher level of neurohormone is registered with anterior unlike posterior ECG localization of MI; at high unlike moderate risk on the GRACE scale; when complicated unlike the uncomplicated course of MI; in the case of acute HF and cardiac arrhythmias unlike patients with the absence of these manifestations in the acute period of MI.

Conclusions. High variability of ST2 level in plasma was demonstrated in patients with NSTEMI on the first day after destabilization (minimum and maximum values – 12.7 and 233.9 respectively, median – 35.9 and interquartile range – 25.9 and 55.7 ng / ml).

It is shown that significantly higher ST2 level in plasma is determined in patients with acute MI regardless of its variant among different clinical forms of CAD.

It is found that significantly higher level of ST2 in patients with NSTEMI is recorded in the case of concomitant HTN and type 2 diabetes, with smoking and heavy cardiovascular heredity. Proved influence of the character of MI course on the level of ST2 in plasma, significantly higher level of neurohormone was determined with anterior localization of MI, high risk on the GRACE scale (≥ 140 points), complicated course of MI, development of cardiac arrhythmias and HF in the acute period of MI.


NSTEMI; biomarkers; ST2; GRACE scale

Full Text:



Nichols, M., Townsend, N., Scarborough, P., Rayner, M. (2013). Cardiovascular disease in Europe: epidemiological update. European Heart Journal, 34 (39), 3028–3034. doi:

Kovalenko, V. M., Kornatskiy, V. M.; Kovalenko, V. M., Kornatskiy, V. M. (Eds.) (2014). Circulation system diseases as medical-social and social-politic problem. Kyiv, 279.

Karetnikova, V. N., Kashtalap, V. V., Kosareva, S. N., Barbarash, O. L. (2017). Fibroz miokarda: sovremennye aspekty problemy. Terapevticheskii arhiv, 89 (1), 88–93.

O’Malley, R. G., Bonaca, M. P., Scirica, B. M., Murphy, S. A., Jarolim, P., Sabatine, M. S. et. al. (2014). Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 63 (16), 1644–1653. doi:

Piper, S. E., Sherwood, R. A., Amin-Youssef, G. F., Shah, A. M., McDonagh, T. A. (2015). Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. International Journal of Cardiology, 178, 284–291. doi:

Gruson, D., Lepoutre, T., Ahn, S. A., Rousseau, M. F. (2014). Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. International Journal of Cardiology, 172 (1), e250–e252. doi:

Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J. et. al. (2014). Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. Journal of the American College of Cardiology, 63 (2), 158–166. doi:

Villacorta, H., Maisel, A. S. (2016). Soluble ST2 Testing: Promising Biomarker in the Management of Heart Failure. Arquivos Brasileiros de Cardiologia, 106, 145–152. doi:

Mueller, T., Dieplinger, B. (2013). The Presage®ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Review of Molecular Diagnostics, 13 (1), 13–30. doi:

Bayes-Genis, A., Januzzi, J. L., Gaggin, H. K., de Antonio, M., Motiwala, S. R., Zamora, E. et. al. (2015). ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. Journal of Cardiac Failure, 21 (4), 355–361. doi:

Lupón, J., Gaggin, H. K., de Antonio, M., Domingo, M., Galán, A., Zamora, E. et. al. (2015). Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. International Journal of Cardiology, 184, 337–343. doi:

Gaggin, H. K., Szymonifka, J., Bhardwaj, A., Belcher, A., De Berardinis, B., Motiwala, S. et. al. (2014). Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure, 2 (1), 65–72. doi:

Vargas, K. G., Kassem, M., Mueller, C., Wojta, J., Huber, K. (2016). Copeptin for the early rule-out of non-ST-elevation myocardial infarction. International Journal of Cardiology, 223, 797–804. doi:

Raskovalova, T., Twerenbold, R., Collinson, P. O., Keller, T., Bouvaist, H., Folli, C. et. al. (2013). Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 3 (1), 18–27. doi:

Lassus, J., Gayat, E., Mueller, C., Peacock, W. F., Spinar, J., Harjola, V.-P. et. al. (2013). Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology, 168 (3), 2186–2194. doi:

Maisel, A. S., Richards, A. M., Pascual-Figal, D., Mueller, C. (2015). Serial ST2 Testing in Hospitalized Patients With Acute Heart Failure. The American Journal of Cardiology, 115 (7), 32B–37B. doi:

Barbarash, O., Gruzdeva, O., Uchasova, E., Dyleva, Y., Belik, E., Akbasheva, O. et. al. (2016). Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. Annals of Laboratory Medicine, 36 (4), 313–319. doi:

O’Malley, R. G., Bonaca, M. P., Scirica, B. M., Murphy, S. A., Jarolim, P., Sabatine, M. S. et. al. (2014). Prognostic Performance of Multiple Biomarkers in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 63 (16), 1644–1653. doi:

Ciccone, M., Cortese, F., Gesualdo, M., Riccardi, R., Di Nunzio, D., Moncelli, M. et. al. (2013). A Novel Cardiac Bio-Marker: ST2: A Review. Molecules, 18 (12), 15314–15328. doi:

Januzzi, J. L., Pascual-Figal, D., Daniels, L. B. (2015). ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. The American Journal of Cardiology, 115 (7), 70B–75B. doi:



  • There are currently no refbacks.

Copyright (c) 2020 Iryna Mezhiievska, Valerii Ivanov, Valentyn Maslovskyi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)